Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT

Core Insights - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a strong buy stock by Wall Street, with a price target set at $85.00 by Raymond James [1] - The company reported total revenues of $825 million in fiscal Q2 2025, reflecting a 16% year-over-year increase and a 17% increase at constant currency [2] - GAAP diluted earnings per share (EPS) for the quarter reached $1.23 [2] - BioMarin specializes in developing and commercializing therapies for serious and life-threatening medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [3]